We have preliminarily identified ML324, discovered as a selective histone demethylase JMJD2/KDM4 inhibitor, has a notable inhibitory impact on the growth of bladder cancer organoids in both mouse and human models, showing superior efficacy compared to other KDM4 inhibitors (IOX1 and JIB-04, sFig. 1A and 1B). Here, KDM4A is linked to urinary bladder carcinoma.